Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:

Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma: A Prospective Phase II Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04851132
• Other study ID #: NCC2840
• Status: Recruiting
• Phase: N/A
• Start date: March 11, 2021
• Est. completion date: June 2023

Study information

• Verified date: June 2021
• Source: Chinese Academy of Medical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The incidence and mortality of esophageal cancer are at the forefront in China, among which the elderly patients account for a large proportion. Concurrent chemoradiotherapy is the standard treatment for inoperable locally advanced esophageal cancer. Most elderly patients with esophageal cancer cannot tolerate concurrent chemotherapy because of complications and other reasons. Immunotherapy has definite efficacy and low toxicity in advanced esophageal squamous cell carcinoma, and the results combined with radiotherapy have also been preliminarily reported. Therefore, it is necessary to further explore the efficacy and safety of radiotherapy combined with immunotherapy in elderly patients with esophageal cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 33
• Est. completion date: June 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

1. Age 70-85 years old, both men and women

2. Histologically confirmed esophageal squamous cell carcinoma located in thoracic segment, treatment naive

3. Stage cT2-4aNanyM0 (AJCC 8 TNM classification)

4. Unresectable, unable to tolerate or refuse surgery and concurrent chemoradiotherapy

5. ECOG PS 0-2

6. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1

7. No severe abnormalities of the Hematologic system, heart, lung, liver, kidney, and immunodeficiency

8. Adequate bone marrow and organ function as defined below (excluding the use of any blood components and cell growth factors within 7 days):

• Absolute neutrophil count=1,500/mm3

• Platelets = 100,000/mm3

• Hemoglobin = 5.6 mmol/L (9g/dL)

• Serum creatinine = 1.5 x ULN or Creatinine clearance =50 mL/min by Cockcroft-Gault estimation

• Total bilirubin = 1.5 x ULN

• ALT and AST = 2.5 x ULN

• Proteinuria < 2+, for subjects with urine protein = 2 + at baseline, urine samples should be collected within 24 hours and urine protein in 24 hours should be = 1g

9. INR or PT or aPTT = 1.5 x ULN

10. Life expectancy more than 6 months

11. Ability to understand and willingness to sign an IRB approved written informed consent document, and capable of proper therapeutic compliance, and accessible to correct follow-up

Exclusion Criteria:

1. Complete esophageal obstruction that unable to eat fluid and cannot provide necessary nutrition through nasal feeding

2. Patients with obvious ulcer or esophageal perforation or hematemesis

3. Placement of esophagotracheal stents

4. Has a history or current evidence of pulmonary fibrosis, interstitial pneumonia, pneumonoconiosis, drug-associated pneumonia, severe impairment of pulmonary function

5. Has had major surgery within 28 days prior to the start of the treatment

6. Immunosuppressive drugs used within 4 weeks prior to the initial study treatment, excluding local glucocorticoids, or systemic glucocorticoids at physiological doses (i.e., no more than 10 mg/ day of prednisone or equivalent doses of other glucocorticoids);

7. The patient has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, glomerulonephritis, thyroiditis (patients with vitiligo or asthma has been completely relieved in childhood, and do not need any intervention during adulthood can be included; patients with type I diabetes with good insulin control can also be included; hypothyroidism caused by autoimmune thyroiditis requiring hormone replacement therapy can also be included)

8. Has had congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV-DNA = 104 copies/ml) or hepatitis C (HCV-RNA = 103 copies/ml; For chronic hepatitis B virus carriers, HBV viral load must be < 2000 IU/ml (< 104 copies / ml), and must receive antiviral therapy at the same time before they can be enrolled

9. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation

10. Uncontrolled clinically significant disease, including active infection, uncontrolled hypertension, unstable angina pectoris, angina within the past 3 months, heart failure > NYHA II, myocardial infarction within the past 6 months, severe arrhythmias requirement for treatment or intervention, liver/kidney or metabolic disease

11. System infections that require treatment

12. Received a live vaccine within 4 weeks of the first dose of study medication

13. Synchronous or metachronous second primary malignancy. Participants with basal cell carcinoma of the skin, or cervical cancer in situ that have undergone potentially curative therapy are not excluded from the study

14. Patients who have participated in other clinical trials within 30 days

15. Drug addiction, chronic alcoholism and AIDS

16. Patients with uncontrollable seizures or loss of self-control due to mental illness

17. Those with a history of severe allergy or specific physique

18. The investigators judge not suitable for inclusion

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Intervention

Radiation:
• Radiotherapy
IMRT (Intensity Modulated RT) or 3D-CRT (three-dimensional conformal radiotherapy); 95% PGTV 59.92Gy/2.14Gy/28f; 95% GTVnd 59.92Gy/2.14Gy/28f; 95% PTV 50.40Gy/1.80Gy/28f; 5 days a week; 6 weeks.

Drug:
• Durvalumab
Durvalumab 1000 mg, intravenously (IV), on Day 1 of radiotherapy, every 3 weeks for up to 18 administrations.

Locations

Country	Name	City	State
China	National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Chinese Academy of Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quality of Life (QOL): questionnaire EORTC QLQ-OES18	Evaluate the quality of life via questionnaire EORTC QLQ-OES18, minimum value 18, maximum value 72, higher scores mean a better outcome.	up to 60 weeks
Primary	Progression-free survival (PFS)	PFS was assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1. Progression-free survival defined as the time from enrollment to the first documented disease progression of local recurrence or distant metastasis or death due to any cause.	1-year
Secondary	Overall survival (OS)	Overall survival defined as the time from enrollment to death due to any cause.	1-, 2- and 3-year
Secondary	Progression-free survival (PFS)	PFS was assessed by Response Evaluation Criteria in Solid Tumors (RECIST)1.1. Progression-free survival defined as the time from enrollment to the first documented disease progression of local recurrence or distant metastasis or death due to any cause.	2- and 3-year
Secondary	Objective Response Rate (ORR)	ORR was Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).	during the intervention up to 60 weeks
Secondary	Disease Control Rate (DCR)	DCR was Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).	during the intervention up to 60 weeks
Secondary	Number of participants with an adverse event	Evaluanted by CTCAE 5.0	Up to 60 weeks
Secondary	Quality of Life (QOL): questionnaire EORTC QLQ-C30 (version 3)	Evaluate the quality of life via questionnaire EORTC QLQ-C30 (version 3), minimum value 30, maximum value 126, higher scores mean a worse outcome.	up to 60 weeks